This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on august 10, 2018.(b)(4).The actual device was not returned for evaluation.A review of the provided photographs found the presence of some substances which were likely to be white thrombus formation on the surface of the oxygenator filter; however, that is not able to be confirmed.There were no anomalies noted in the production related records of the involved product code/lot number combination.Without the returned device and no additional information, a root cause can not be determined.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|